The firm focuses on investing in European life science companies developing therapeutics for humans, particularly specialty pharmaceuticals and orphan drugs. They prefer to invest in companies with clear exit strategies and target companies in Norway, Denmark, Finland, Sweden, Germany, and Switzerland. Notable investments include IO Biotech, OxThera, and Antargia.